TOBRAMYCIN and COUGH

Overview

COUGH is the #7 most commonly reported adverse reaction for TOBRAMYCIN, manufactured by Viatris Specialty LLC. There are 1,257 FDA adverse event reports linking TOBRAMYCIN to COUGH. This represents approximately 3.4% of all 37,207 adverse event reports for this drug.

Patients taking TOBRAMYCIN who experience cough should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

COUGH is moderately reported among TOBRAMYCIN users, representing a notable but not dominant share of adverse events.

Other Side Effects of TOBRAMYCIN

In addition to cough, the following adverse reactions have been reported for TOBRAMYCIN:

• OFF LABEL USE — 1,939 reports
• DEATH — 1,668 reports
• INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS — 1,560 reports
• PNEUMONIA — 1,452 reports
• DYSPNOEA — 1,373 reports
• CYSTIC FIBROSIS — 1,263 reports
• HOSPITALISATION — 996 reports
• CONDITION AGGRAVATED — 942 reports
• INFECTION — 832 reports
• DRUG INEFFECTIVE — 818 reports

Other Drugs Associated with COUGH

The following drugs have also been linked to cough in FDA adverse event reports:

Does TOBRAMYCIN cause COUGH?

COUGH has been reported as an adverse event in 1,257 FDA reports for TOBRAMYCIN. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is COUGH with TOBRAMYCIN?

COUGH accounts for approximately 3.4% of all adverse event reports for TOBRAMYCIN, making it a notable side effect.

What should I do if I experience COUGH while taking TOBRAMYCIN?

If you experience cough while taking TOBRAMYCIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages